6.19.20 | Coronavirus
SWHR Urges Inclusion of At-Risk Women in COVID-19 Research
SWHR joined 25 organizations in urging the Food and Drug Administration (FDA) and National Institutes of Health (NIH) to include […]
6.17.20 | Policy
SWHR Comments to CDC on Management of Acute and Chronic Pain
SWHR provided the Centers for Disease Control and Prevention (CDC) with requested comments on Management of Acute and Chronic Pain. […]
5.21.20 | Policy
SWHR Testimony on HHS Appropriations for FY2021
This week, SWHR President and CEO Kathryn G. Schubert, MPP, provided outside witness testimony on behalf of the Society for […]
5.19.20 | Research and Clinical Trials
SWHR Comments on Cures 2.0 Legislation
SWHR provided Representative Diana DeGette (D-CO) and Representative Fred Upton (R-MI) with initial feedback today in response to their recent […]
4.21.20 | Alzheimer's Disease
SWHR Comments on AHRQ Draft Report on Dementia Caregiving
SWHR provided comments on the Care Interventions of People with Dementia and for their Caregivers draft report by the Agency […]
3.18.20 | Coronavirus
SWHR Urges Inclusion of Pregnant and Lactating Women in COVID-19 Research
SWHR and other members of the Coalition to Advance Maternal Therapeutics (CAMT) urged the National Institutes of Health (NIH) and […]
3.13.20 | Alzheimer's Disease
SWHR Feedback to Senate Finance Health Subcommittee on Alzheimer’s Research Priorities
SWHR sent comments to the Senate Finance Subcommittee on Health Care in response to its call for feedback related to […]
12.23.19 | Policy
SWHR Feedback to FDA on Health of Women Strategic Plan
In comments to the U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH), SWHR provided feedback on […]
10.22.19 | Policy
SWHR Urges Women’s Health Focus in U.S. Biotechnology Investment
In a letter to the White House Office of Science and Technology Policy (OSTP), SWHR recommended the government prioritize biotechnology […]
10.18.19 | Policy
SWHR Recommendations on ICER’s 2020 Value Assessment Framework
SWHR provided recommendations to the Institute for Clinical and Economic Review (ICER) on proposed changes to its 2020 value assessment […]
